Diabetes Care:与1型糖尿病病程和血管并发症相关的认知功能缺损!

2018-06-06 xing.T MedSci原创

由此可见,1型糖尿病患者和2型糖尿病患者总体认知能力均明显低于对照组。此外,在50岁以上的1型糖尿病患者中,观察到了并发症与认知之间的关系。虽然两组糖尿病患者表现出相似的赤字模式,但其潜在机制可能不同。当前,1型糖尿病患者的寿命延长,应努力评估认知和识别可改变的行为,以减缓下降。

1型糖尿病患者现在存活时间较长足以经历认知衰退的过程。在中年期间,他们表现出轻度认知缺陷,但严重程度不知道是否会随着年龄的增长而增加或认知功能是否类似于年龄匹配的伴有糖尿病和不伴有糖尿病的同伴。

近日,糖尿病领域权威杂志Diabetes Care上发表了一篇研究文章,研究人员对82名50岁以上的1型糖尿病患者、31名年龄匹配的2型糖尿病患者和30名年龄匹配的无糖尿病对照者进行了认知测试和比较。研究人员收集受试者病史和生物标志物,还评估了50岁以上的1型糖尿病患者并发症与认知之间的相关性。

与对照组相比,1型糖尿病患者和2型糖尿病患者在即刻和延迟回忆(P<0.002)和精神运动速度方面表现较差(P<0.01),表现为执行功能较差(P=0.05)。在50岁以上的1型糖尿病患者中,心血管疾病与执行功能减退和增生性糖尿病视网膜病变相关,其运动速度较慢。

由此可见,1型糖尿病患者和2型糖尿病患者总体认知能力均明显低于对照组。此外,在50岁以上的1型糖尿病患者中,观察到了并发症与认知之间的关系。虽然两组糖尿病患者表现出相似的赤字模式,但其潜在机制可能不同。当前,1型糖尿病患者的寿命延长,应努力评估认知和识别可改变的行为,以减缓下降。

原始出处:

Gail Musen,et al. Cognitive Function Deficits Associated With Long-Duration Type 1 Diabetes and Vascular Complications.Diabetes Care.2018. https://doi.org/10.2337/dc17-1955

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1638641, encodeId=7b34163864106, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 01 03:21:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760707, encodeId=1e0b1e60707ea, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 01 23:21:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902074, encodeId=e9bf19020e4d2, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Oct 23 01:21:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757995, encodeId=d3221e57995f4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Jan 18 17:21:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545358, encodeId=39e71545358b7, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Fri Jun 08 05:21:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321961, encodeId=d2bd321961f7, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 06 15:44:25 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1638641, encodeId=7b34163864106, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 01 03:21:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760707, encodeId=1e0b1e60707ea, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 01 23:21:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902074, encodeId=e9bf19020e4d2, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Oct 23 01:21:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757995, encodeId=d3221e57995f4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Jan 18 17:21:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545358, encodeId=39e71545358b7, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Fri Jun 08 05:21:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321961, encodeId=d2bd321961f7, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 06 15:44:25 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1638641, encodeId=7b34163864106, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 01 03:21:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760707, encodeId=1e0b1e60707ea, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 01 23:21:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902074, encodeId=e9bf19020e4d2, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Oct 23 01:21:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757995, encodeId=d3221e57995f4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Jan 18 17:21:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545358, encodeId=39e71545358b7, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Fri Jun 08 05:21:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321961, encodeId=d2bd321961f7, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 06 15:44:25 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1638641, encodeId=7b34163864106, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 01 03:21:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760707, encodeId=1e0b1e60707ea, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 01 23:21:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902074, encodeId=e9bf19020e4d2, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Oct 23 01:21:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757995, encodeId=d3221e57995f4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Jan 18 17:21:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545358, encodeId=39e71545358b7, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Fri Jun 08 05:21:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321961, encodeId=d2bd321961f7, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 06 15:44:25 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2019-01-18 丁鹏鹏
  5. [GetPortalCommentsPageByObjectIdResponse(id=1638641, encodeId=7b34163864106, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 01 03:21:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760707, encodeId=1e0b1e60707ea, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 01 23:21:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902074, encodeId=e9bf19020e4d2, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Oct 23 01:21:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757995, encodeId=d3221e57995f4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Jan 18 17:21:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545358, encodeId=39e71545358b7, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Fri Jun 08 05:21:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321961, encodeId=d2bd321961f7, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 06 15:44:25 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1638641, encodeId=7b34163864106, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jul 01 03:21:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760707, encodeId=1e0b1e60707ea, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 01 23:21:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902074, encodeId=e9bf19020e4d2, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Oct 23 01:21:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757995, encodeId=d3221e57995f4, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Jan 18 17:21:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545358, encodeId=39e71545358b7, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Fri Jun 08 05:21:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321961, encodeId=d2bd321961f7, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 06 15:44:25 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2018-06-06 1ddf0692m34(暂无匿称)

    学习了.长知识

    0

相关资讯

Diabetologia:童年型1型糖尿病影响劳动力市场的中介效应分析

近日,国际杂志 《Diabetologia》上在线发表一项关于为什么童年型1型糖尿病影响劳动力市场结果的中介效应分析的研究。 以前的研究表明1型糖尿病会对劳动力市场结果产生负面影响,比如就业和后期收入。然而,目前关于这些影响的机制知之甚少。本研究旨在分析成人健康,教育,职业和家庭的中介效应作用。 本研究共包括瑞典儿童糖尿病登记册共有4179人,并以在1962年至1979年间出生的167

Diabetologia:1型糖尿病遗传易感性儿童的血液转录组学中肠道病毒相关的变化

近日,国际杂志 《Diabetologia》上在线发表一项关于1型糖尿病遗传易感性儿童的血液转录组学中肠道病毒相关的变化的研究。 多项研究表明肠道病毒感染与1型糖尿病的发展有关,但对有发生1型糖尿病风险的儿童肠道病毒诱导的反应知之甚少。研究人员的目标是使用全基因转录组学数据来描述患有1型糖尿病遗传易感性的儿童的全血样品中肠道病毒相关的变化的特征。 研究人员从28对患1型糖尿病的风险增加

Diabetologia:在1型糖尿病小鼠模型中膜联蛋白A1通过恢复Akt信号传导来减弱微血管并发症

近日,国际杂志 《Diabetologia》上在线发表一项关于在1型糖尿病小鼠模型中膜联蛋白A1通过恢复Akt信号传导来减弱微血管并发症的研究。 心脏和肾脏中的微血管并发症与炎症的整体升高密切相关。膜联蛋白A1(ANXA1)是限制和消除炎症的内源性抗炎分子。在这项研究中,研究人员使用a bedside to bench approach方法来调查:(1)1型糖尿病患者的ANXA1水平;(2)

Diabetologia:12岁以下儿童出生体重,出生时胎龄与1型糖尿病之间的关联?

近日,国际杂志 《Diabetologia》上在线发表关于12岁以下儿童出生体重,出生时胎龄与后期患1型糖尿病之间的关联的一项1998-2012年在英国进行的回顾性队列研究的研究。 遗传学仅能够解释1型糖尿病风险的40-50%,但同时,早期生活中的环境风险因素也是1型糖尿病的风险因素。以前的研究发现1型糖尿病的出生时体重和出生时胎龄不一致。本研究旨在调查英国出生体重,出生时胎龄与随后的1型糖

Cell Rep:新技术成功治疗小鼠糖尿病!

近日,科学家利用组织工程学方法在实验室中对人类胰岛细胞进行改造,使其能够形成循环系统,并分泌胰岛素等激素,还能成功治疗小鼠突发的1型糖尿病。这项研究已发表在5月8日的《Cell Reports》上,由美国辛辛那提儿童医院医疗中心和日本横滨市立大学(YCU)合作完成。

Diabetologia:持久的HbA1C改善很少发生1型糖尿病5年后及其临床意义

近日,国际杂志 《Diabetologia》上在线发表一项关于持久的HbA1C改善很少发生1型糖尿病5年后及其临床意义:一个有关早期,针对性和积极的干预下诊断争论的研究。 研究人员的目标是探索1型糖尿病患者是否有HbA1C “跟踪”现象,诊断后多长时间跟踪变得稳定,以及是否性别和年龄会在跟踪诊断的上有效果。 研究人员健康改善网络(THIN)数据库中共确认了1995年1月1日至2015年